Cocrystal Pharma Files 8-K on Financials

Ticker: COCP · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1412486

Cocrystal Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type8-K
Filed DateNov 13, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

Cocrystal Pharma dropped an 8-K, check it for financial updates.

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This filing signals that Cocrystal Pharma, Inc. is providing updated financial information and operational details to the SEC, which is crucial for investors to assess the company's current standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting financial condition and does not inherently indicate new risks or significant negative events.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific financial figures within this excerpt.

When was the earliest event reported in this filing?

The earliest event reported is dated November 13, 2024.

What is the principal executive office address for Cocrystal Pharma, Inc.?

The principal executive office is located at 19805 N. Creek Parkway, Bothell, WA 98011.

What is the SEC file number for Cocrystal Pharma, Inc.?

The SEC file number is 001-38418.

What is the IRS Employer Identification Number for Cocrystal Pharma, Inc.?

The IRS Employer Identification Number is 35-2528215.

Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-13 15:30:11

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cocrystal Pharma, Inc. Date: November 13, 2024 By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing